Introducing the Resonant panel

Monitor cell-specific biomarkers
of neurodegeneration with our
screening tools.

*Our screening tools for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) are currently undergoing validation with patient blood samples.

Unlock Earlier Insights Into Neurodegeneration

Resonant’s tests are designed to detect cell-free DNA (cfDNA) from dying neurons. We’re developing a method that not only detects elevated cfDNA in the blood but also identifies its cell-of-origin. This offers the potential for cell type-specific snapshots of neurodegeneration in the brain.

Our panel aims to provide physicians with insights that may help patients make informed decisions and preserve their quality of life.

A Novel Liquid Biopsy Approach to Support Earlier, cell-specific insights into neurodegeneration.

The Impact

75%

Of individuals with dementia,
including Alzheimer’s disease,
are undiagnosed.¹

9-24

Months is the average delay
in ALS diagnosis.²

40-60%

Of dopamine neurons in the substantia nigra have already been lost at the clinical onset of Parkinson’s disease.³

Recent Studies

Resonant has recently completed a large study targeting 3 neuron types associated with neurodegenerative diseases:

Cortical Neurons in Alzheimer's disease
Dopamine Neurons in Parkinson's disease
Motor Neurons in Amyotrophic lateral sclerosis

Data Available Soon

To learn more about our research, email: contact@resonantdx.com

Looking Ahead: Accessing Our Tests

1. Create an account in Resonant’s Provider Portal.

2. Collect blood samples from your patients.

3. Package and ship samples to Resonant.

4. Track samples and receive real-time updates.

Be the first to know when physician ordering is available:

Fill Out The Form

Introducing the Resonant panel

Monitor cell-specific biomarkers
of neurodegeneration with our
screening tools.

Unlock Earlier Insights Into Neurodegeneration

The Resonant panel Timeline

A Novel Liquid Biopsy Approach to Support Earlier, cell-specific insights into neurodegeneration.

The Impact

75%

Of individuals with dementia,
including Alzheimer’s disease,
are undiagnosed.¹

9-24

Months is the average delay
in ALS diagnosis.²

40-60%

Of dopamine neurons in the substantia nigra have already been lost at the clinical onset of Parkinson’s disease.³

Recent Studies

Resonant has recently completed a large study targeting 3 neuron types associated with neurodegenerative diseases:

Cortical Neurons in Alzheimer's disease
Dopamine Neurons in Parkinson's disease
Motor Neurons in Amyotrophic lateral sclerosis

Data Available Soon

To learn more about our research, email: contact@resonantdx.com

Looking Ahead: Accessing Our Tests

1. Create an account in Resonant’s Provider Portal.

2. Collect blood samples from your patients.

3. Package and ship samples to Resonant.

4. Track samples and receive real-time updates.

Be the first to know when physician ordering is available:

Sign Up For Our Newsletter

Introducing the Resonant panel

Monitor cell-specific biomarkersof neurodegeneration with ourscreening tools.

Unlock Earlier Insights Into Neurodegeneration

The Resonant panel Timeline

A Novel Liquid Biopsy Approach to Support Earlier, cell-specific insights into neurodegeneration.

The Impact

75%

Of individuals with dementia, including Alzheimer’s disease, are undiagnosed.1

9-24

Months is the average delay in ALS diagnosis.2

40-60%

Of dopamine neurons in the substantia nigra have already been lost at the clinical onset of Parkinson’s disease.3

Recent Studies

Resonant has recently completed a large study targeting 3 neuron types associated with neurodegenerative diseases:

Cortical Neurons in Alzheimer's disease Dopamine Neurons in Parkinson's disease Motor Neurons in Amyotrophic lateral sclerosis

Data Available Soon

To learn more about our research, email: contact@resonantdx.com

Looking Ahead: Accessing Our Tests

1. Create an account in Resonant’s Provider Portal.

2. Collect blood samples from your patients.

3. Package and ship samples to Resonant.

4. Track samples and receive real-time updates.

Be the first to know when physician ordering is available:

Thanks for joining our Provider waitlist!

Sign Up For Our Newsletter

Monitor cell-specific biomarkers
of neurodegeneration with our
screening tools.

Of individuals with dementia,
including Alzheimer’s disease,
are undiagnosed.¹

Months is the average delay
in ALS diagnosis.²

Of dopamine neurons in the substantia nigra have already been lost at the clinical onset of Parkinson’s disease.³

Cortical Neurons in Alzheimer's disease
Dopamine Neurons in Parkinson's disease
Motor Neurons in Amyotrophic lateral sclerosis